INSP$86.78
Chart
Performance
Key Stats
AI INSP Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyInspire Medical Systems shows strong long-term potential driven by its innovative solution for sleep apnea, with a solid fundamental base. However, current technical indicators suggest caution due to recent price declines and mixed short-term signals. The thematic alignment with health tech is a significant positive.
Thematic
Inspire Medical Systems is well-positioned within the growing health technology sector, specifically addressing the significant market of obstructive sleep apnea (OSA). The company's minimally invasive solution offers a compelling alternative to traditional treatments, aligning with trends towards advanced medical devices and improved patient outcomes.
Fundamental
Inspire Medical Systems demonstrates robust revenue growth and improving profitability. While the P/E ratio is high, it reflects the company's growth potential in a specialized market. The balance sheet is strengthening with increasing cash reserves and manageable debt levels.
Technical
The stock has experienced a significant decline from its 52-week high, trading below key moving averages. While some short-term indicators show potential for a bounce, the overall trend is bearish, suggesting a need for confirmation before considering a bullish position.
| Factor | Score |
|---|---|
| Healthcare Innovation | 95 |
| Aging Population & Chronic Diseases | 90 |
| Minimally Invasive Procedures | 85 |
| Regulatory Environment (Healthcare) | 75 |
| Market Penetration | 70 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 65 |
| Growth | 80 |
| Balance Sheet Health | 75 |
| Cash Flow | 85 |
| Debt Management | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 70 |
| Support & Resistance | 60 |
| Oscillators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
Inspire Medical Systems (INSP) has consistently exceeded EPS estimates in recent quarters, with surprises ranging from 14.7% to 696.9%, indicating strong operational execution and better-than-expected profitability.
Improving Valuation Metrics
While the Price-to-Earnings (P/E) ratio is high, the Price-to-Sales (P/S) ratio has improved significantly from 29.1 in Q4 2021 to 6.8 in Q4 2024, suggesting growing revenue is becoming more efficient in generating value.
Bearish Points (7)
High P/E Ratio
The trailing twelve months (TTM) P/E ratio stands at 66.9, and the forward P/E for 2024 is 102.2, which is significantly higher than industry averages, suggesting potential overvaluation and higher risk of price correction.
Slowing Revenue Growth
While the company has achieved profitability, quarterly revenue growth has shown volatility, with a notable slowdown in Q1 2025 to 1.5% net margin, raising concerns about sustained top-line expansion.
Calendar
August 2025
5
Next Earnings Date
H: $0.27
A: $0.20
L: $0.12
H: 217.60M
A: 214.34M
L: 211.23M
Profile
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Seasonals
Price Target
208.30 USD
The 39 analysts offering 1 year price forecasts for INSP have a max estimate of 270.00 and a min estimate of 149.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading global developer and manufacturer of sleep apnea and respiratory care devices, a primary competitor in the broader sleep apnea market, though focused on CPAP.
Weight: 90
Major player in sleep and respiratory care, offering CPAP machines, ventilators, and related solutions, making it a key competitor in the wider sleep disorder treatment space.
Weight: 88
Specializes in neuromodulation (VNS Therapy for epilepsy/depression), sharing core implantable neurostimulation technology and regulatory pathways with INSP.
Weight: 85
Develops and commercializes sacral neuromodulation systems, a direct peer in the implantable neurostimulation device market with similar technological and operational considerations.